2438-03-1

Basic information

• Product Name: 2-Propylbenzoic acid
• Synonyms: 2-Propylbenzoic acid;Benzoic acid, 2-propyl-
• CAS NO: 2438-03-1
• Molecular Formula: C₁₀H₁₂O₂
• Molecular Weight: 164.2
• Mol File: 2438-03-1.mol

Chemical Properties

• Melting Point: 58°C
• Boiling Point: 288.61°C (estimate)
• Appearance: /
• Density: 1.0020
• Refractive Index: 1.5232 (estimate)
• PKA: 4.15±0.36(Predicted)
• CAS DataBase Reference: 2-Propylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propylbenzoic acid(2438-03-1)
• EPA Substance Registry System: 2-Propylbenzoic acid(2438-03-1)

Safety Data

• Hazardous Substances Data: 2438-03-1(Hazardous Substances Data)

Upstream product

• 17475-41-1 3-ethylphthalide 
• 118-90-1 ortho-methylbenzoic acid 
• 75-03-6 ethyl iodide 
• 108-86-1 bromobenzene 
• 65946-52-3 1-Ethoxy-1-trimethylsilyloxy-1-buten 
• 108-90-7 chlorobenzene 
• 10034-85-2 hydrogen iodide 
• 14120-20-8 2-(3-oxo-3H-isobenzofuran-1-ylidene)-propionic acid 
• 75-44-5 phosgene 
• 22975-62-8 1-isopropyl-4-propyl-benzene 
• 7697-37-2 nitric acid 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 1041642-22-1 2-(n-Propyl)-benzoesaeuremethylester 
• 61463-59-0 2-allyl benzoic acid methyl ester 

Downstream Products

• 1041642-22-1 2-(n-Propyl)-benzoesaeuremethylester 
• 177903-43-4 (2-Propyl-benzoyl)-phosphonic acid dimethyl ester 
• 1036390-52-9 C₂₁H₂₂N₂O₅ 
• 1036390-44-9 C₁₁H₁₃NO₄ 
• 63620-04-2 2-propyl-benzoyl chloride 
• 97567-64-1 2-n-Propylbenzonitrile 

Relevant articles and documents

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Selective aerobic oxidation of alkyl aromatics on Bi2MoO6 nanoplates decorated with Pt nanoparticles under visible light irradiation

Pt/Bi2MoO6 nanoplates are efficient photocatalysts for the selective oxidation of saturated C-H bonds in alkyl aromatics under visible light illumination using O2 as an oxidant. This study opens a new window for direct C-H functionalization through the photocatalytic method based on cheap Bi2MoO6 semiconductor materials.

6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

Inclusion complex containing epoxy resin composition for semiconductor encapsulation

The invention is an epoxy resin composition for sealing a semiconductor, including (A) an epoxy resin and (B) a clathrate complex. The clathrate complex is one of (b1) an aromatic carboxylic acid compound, and (b2) at least one imidazole compound represented by formula (II): wherein R2 represents a hydrogen atom, C1-C10 alkyl group, phenyl group, benzyl group or cyanoethyl group, and R3 to R5 represent a hydrogen atom, nitro group, halogen atom, C1-C20 alkyl group, phenyl group, benzyl group, hydroxymethyl group or C1-C20 acyl group. The composition has improved storage stability, retains flowability when sealing, and achieves an effective curing rate applicable for sealing delicate semiconductors.

Pincer thioamide and pincer thioimide palladium complexes catalyze highly efficient negishi coupling of primary and secondary alkyl zinc reagents at room temperature

Pincer thioamide PdII complex 2 was prepared, and its reaction with cyclohexylzinc chloride yielded novel pincer thioimide PdII complex 3 besides Pd0 species. The structures of complexes 2 and 3 were confirmed by X-ray ana